



Medi-Cal Rx

Changes to the Medi-Cal Rx Contract Drugs List

May 1, 2025

The following changes have been made to the [Medi-Cal Rx Contract Drugs List](#) and the [Medi-Cal Rx Diagnosis Crosswalk](#) * posted to the Medi-Cal Rx Web Portal, effective May 1, 2025.

Drug Name	Description	Effective Date
Dalfampridine	* Added to <i>Medi-Cal Rx Contract Drugs List</i> (CDL) with age and diagnosis restrictions.	May 1, 2025
Dimethyl Fumarate	* Added to the CDL with age and diagnosis restrictions.	May 1, 2025
Diphtheria/Tetanus Toxoids/Acellular Pertussis/Inactivated Poliovirus Vaccine	Additional strength (15-48-5-62/0.5 ml vial) added to the CDL.	May 1, 2025
Lebrikizumab-lbkz	* Added to the CDL with age, diagnosis, labeler, and quantity restrictions.	May 1, 2025
Maraviroc	Effective June 1, 2025: 25 mg and 75 mg tablets end-dated.	May 1, 2025
Mirvetuximab Soravtansine-gynx	Prior authorization (PA) restriction removed. Labeler restriction (LR) added.	May 1, 2025
Rotavirus Vaccine	Additional dosage form (reconstituted suspension) added to the CDL.	May 1, 2025
Secnidazole	Effective June 1, 2025: LR added.	May 1, 2025
Teriflunomide	* Added to the CDL with age and diagnosis restrictions.	May 1, 2025

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.